Mazdutide

Dual GLP-1 / glucagon agonist (Eli Lilly / Innovent) — emphasis on fat-mass loss and NASH.

Mazdutide pairs GLP-1 with glucagon — the appetite-suppressing arm plus the energy-burning, liver-fat-clearing arm. Originating in Lilly's labs and developed for the Chinese market by Innovent, it became the world's first approved GLP-1/glucagon dual agonist when China's regulator cleared it for weight management in mid-2025. The glucagon component gives it a particular edge on fat-mass loss and liver fat (NAFLD/MASH), with up to ~20% weight loss in its Phase 3 GLORY-2 trial. Lilly retains the rights outside China, where it isn't yet approved.

Dose

Weekly titration from low starting dose.

Reconstitute

Standard reconstitution.

Schedule

Weekly.

Half-life

~5–7 days.

Timing

Same day each week.

Risks

GI side effects similar to other GLPs. Emerging dataset.

Educational reference — not medical advice. Many peptides are not approved for the uses discussed; verify status in your jurisdiction and decide anything here with a qualified clinician.

within Weight Loss & GLP Class